Hyperin; Quercetin 3-galactoside; Hyperosid; Hyperozide; Quercetin-3-O-galactoside; Hyperasid; Jyperin; Quercetin 3-O-beta-D-galactopyranoside; Quercetin 3-D-galactoside; UNII-8O1CR18L82; Quercetin-3-galactoside; Quercetin 3-beta-D-galactopyranoside; MFCD00016933; quercetin 3-O-galactoside; NSC 407304; CHEMBL251254; 8O1CR18L82; QUERCETIN 3-B-D-GALACTOSIDE; CCRIS 9339; p Hyperin; Quercetin 3-.beta.-D-galactopyranoside; Quercetin 3-O-.beta.-D-galactopyranoside; Hyperin,(S); Hyperin (8CI); quercetin-3-d-galactoside; BIDD:PXR0057; MLS000759538; 2-yloxy)-4H-chromen-4-one; jm5b01461, Compound 84; MEGxp0_000392; SCHEMBL1250514; ACon1_000623; Quercetin 3-O-beta-D-galactoside; BDBM429266; HMS2051H17; HY-N0452; quercetin 3-O--D-galactopyranoside; ZINC3973253; BDBM50241367; s5453; AKOS015896780; quercetin 3-O- -D-galactopyranoside; 6-(hydroxymethyl)tetrahydro-2H-pyran-; CCG-100970; MCULE-5363142212; NC00220; AS-56199; SC-43872; SMR000466394; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; CS-0008982; N1838; A12070; C10073; Quercetin 3-D-galactoside, >=97.0% (HPLC); AB00639910-03; 3-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-; 482H360; 3,3',4',5,7-Pentahydroxyflavone 3-D-galactoside; Hyperoside, primary pharmaceutical reference standard; Q-100530; Q5242815; BRD-K84955386-001-01-1; 3-O-b-D-Galactopyranosyloxy-3',4',5,7-tetrahydroxyflavone; Hyperoside, United States Pharmacopeia (USP) Reference Standard; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl hexopyranoside #